Palatin Technologies, Inc. — Form 10-Q Summary
Business context and reporting period
This filing covers the fiscal quarter and six months ended December 31, 2020 (fiscal Q2 2021), with comparisons to the periods ended December 31, 2019. Palatin is a clinical-stage biopharmaceutical company whose FDA-approved product, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder in premenopausal women. Following termination of its North American license with AMAG in July 2020, Palatin assumed responsibility for Vyleesi manufacturing, marketing, and distribution in North America.
Financial performance and liquidity
- Revenue: Product revenue, net, was negative $164,000 for the quarter and negative $453,000 for the six months, reflecting sales allowances exceeding gross sales. Gross product sales were $944,000 for the quarter and $1.753 million for six months; related allowances were $1.108 million and $2.206 million, respectively. There was no license and contract revenue in the 2020 periods. Prior-year license and contract revenue was $20,610 for the quarter and $117,989 for six months.
- Loss and expenses: Net loss was $9.992 million for the quarter versus $5.244 million a year earlier, and $13.933 million for six months versus $9.745 million. Loss per share was $0.04 for the quarter and $0.06 for six months, compared with $0.02 and $0.04, respectively. Quarterly R&D expense rose to $4.011 million from $3.258 million, mainly on melanocortin-receptor programs. Quarterly SG&A increased to $5.045 million from $2.404 million, primarily due to Vyleesi selling costs and higher compensation.
- Cash flow: Operating activities used $10.607 million in the six months, compared with providing $49.915 million in the prior-year period; the prior-year result was affected by timing of AMAG-related receipts. Cash and cash equivalents fell to $72.156 million at December 31, 2020, from $82.852 million at June 30, 2020. Investing cash flow was zero; financing activities used $89,000.
- Liquidity and obligations: Current assets were $85.491 million and current liabilities $7.250 million. Total liabilities were $18.943 million, including $11.693 million of operating lease and other long-term liabilities. No notes payable were outstanding at period end; the historical venture loan had matured. Management believed available cash would fund current operating plans for at least twelve months from issuance of the financial statements, while noting additional funding would be needed for later clinical development.
- Margins: Reported net product revenue was negative after allowances, so a conventional positive product gross margin is not indicated by the filing for these periods.
Material changes versus the prior comparable period
- Palatin regained Vyleesi’s North American rights from AMAG effective July 24, 2020 and began marketing the product itself. The change brought product sales and related commercial costs onto Palatin’s statements, replacing prior license-related revenue.
- For the six months, Palatin recorded a $1.624 million gain on the AMAG termination agreement. AMAG paid $12 million at closing and owed a further $4.3 million receivable at December 31, 2020, scheduled for payment March 31, 2021.
- Operating cash flow shifted from a substantial inflow to an outflow, largely because of the timing of prior-period AMAG receipts. R&D and SG&A spending increased, while investment income declined.
- A $745,000 foreign-currency transaction loss was recorded in the 2020 quarter and six-month period, principally related to foreign-currency-denominated Vyleesi purchase commitments.
Outlook, risks, and unusual items
- No specific revenue, earnings, or product-sales guidance is provided. Management expects continued significant spending on Vyleesi commercialization and on MC1r, MC4r, and natriuretic-peptide development programs; sustained profitability is uncertain.
- Vyleesi supply agreements carry $12.344 million of inventory purchase commitments, including $1.010 million current and $11.334 million due over the following four years. The balance sheet includes $1.010 million current and $10.837 million long-term liabilities for estimated losses on firm commitments. Total disclosed inventory commitments and operating lease obligations were $13.598 million.
- COVID-19 could disrupt commercialization, clinical trials, suppliers, and access to financing. Other key risks include the need for additional capital, uncertain clinical and regulatory outcomes, Vyleesi market acceptance and reimbursement, and currency fluctuations. The filing reports no material changes to the risk factors in the fiscal 2020 Form 10-K.
- Vyleesi is licensed to partners in China and South Korea; regulatory delays could defer potential milestone or royalty income. The filing does not provide a clear amount of future partner revenue.
- Product sales allowances exceeded gross sales in both 2020 periods; estimates for rebates, discounts, and other deductions are therefore important to monitor. The filing also reports a $6 million payment to terminate the former Catalent agreement, followed by a replacement manufacturing agreement with reduced minimum purchase requirements.
Important facts for investors to verify
- Whether Vyleesi net sales improve as Palatin builds its own U.S. commercial operation, and how sales allowances compare with gross sales.
- Collection of AMAG’s $4.3 million receivable and the timing and cash impact of the AMAG termination arrangements.
- Vyleesi demand relative to the company’s committed manufacturing purchases, accrued commitment losses, and remaining supply obligations.
- Cash burn, actual runway versus management’s stated twelve-month assessment, and the need and terms of any future financing.
- Clinical and regulatory progress, COVID-19-related delays, and commercialization progress by the China and Korea licensees.